Thermo Fisher Launches PPD™ CorEvitas™ Obesity Registry To Generate Real-World Evidence On Obesity Therapies

Thermo Fisher Scientific Inc., the world leader in serving science, announced the enrollment of the first patient in the newly launched PPD™ CorEvitas™ Obesity Registry, a prospective, observational initiative designed to generate real-world evidence on obesity management.

The registry will evaluate the long-term effectiveness, safety, and patient experience associated with obesity therapies, including anti-obesity medications, across diverse clinical settings. By integrating clinician-reported and patient-reported data, the initiative aims to provide deeper insight into treatment patterns, adherence, satisfaction, and clinical outcomes, including anthropometric measures over time.

Obesity is a chronic, multifactorial disease influenced by genetic, environmental, and psychosocial factors and is associated with serious comorbidities such as type 2 diabetes, cardiovascular disease, and certain cancers. Beyond physical health, obesity significantly affects quality of life, mobility, and mental health. In the United States alone, more than 100 million adults are living with obesity, including over 22 million with severe obesity. Globally, the economic burden of overweight and obesity is projected to reach $3 trillion annually by 2030, increasing to more than $18 trillion by 2060.

“The CorEvitas Obesity Registry represents a major step forward in understanding the use and outcomes associated with obesity treatments in everyday clinical practice,” said Leslie Harrold, M.D., vice president and global head of real-world science and strategy for PPD CorEvitas Clinical Registries, Thermo Fisher Scientific. “Insights generated from this robust, real-world evidence base will inform the healthcare community on treatment effectiveness, safety and the patient experience associated with obesity care, which will advance care for millions living with the condition.”

The PPD™ CorEvitas™ Obesity Registry is designed to capture detailed longitudinal data to better understand disease progression, treatment response, and real-world challenges encountered by patients throughout their care journey. Insights generated from the registry are expected to support informed clinical decision-making, future research, and the development of evidence-based strategies for managing obesity.

This initiative represents the 15th independent registry established under the PPD™ CorEvitas™ Clinical Registries portfolio, part of Thermo Fisher Scientific’s PPD clinical research business.

The CorEvitas Clinical Registries platform features proprietary disease registries that collect structured, regulatory-grade clinical data from over 500 investigator sites, with longitudinal data from more than 100,000 patients. The CorEvitas independent registry model has been accepted by regulatory authorities worldwide to support long-term post-authorization safety studies across multiple disease areas.